|
1
|
Smith LH and Oi RH: Detection of malignant
ovarian neoplasms: A review of the literature. I. Detection of the
patient at risk; clinical, radiological and cytological detection.
Obstet Gynecol Surv. 39:313–328. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhang Z, Bast RC Jr, Yu Y, Li J, Sokoll
LJ, Rai AJ, Rosenzweig JM, Cameron B, Wang YY, Meng XY, et al:
Three biomarkers identified from serum proteomic analysis for the
detection of early stage ovarian cancer. Cancer Res. 64:5882–5890.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Heintz AP, Odicino F, Maisonneuve P, Quinn
MA, Benedet JL, Creasman WT, Ngan HY, Pecorelli S and Beller U:
Carcinoma of the fallopian tube. FIGO 26th Annual Report on the
Results of Treatment in Gynecological Cancer. Int J Gynaecol
Obstet. 95(Suppl 1): S145–S160. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Enakpene CA, Omigbodun AO, Goecke TW,
Odukogbe AT and Beckmann MW: Preoperative evaluation and triage of
women with suspicious adnexal masses using risk of malignancy
index. J Obstet Gynaecol Res. 35:131–138. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Karlsen MA, Sandhu N, Høgdall C,
Christensen IJ, Nedergaard L, Lundvall L, Engelholm SA, Pedersen
AT, Hartwell D, Lydolph M, et al: Evaluation of HE4, CA125, risk of
ovarian malignancy algorithm (ROMA) and risk of malignancy index
(RMI) as diagnostic tools of epithelial ovarian cancer in patients
with a pelvic mass. Gynecol Oncol. 127:379–383. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Folk JJ, Botsford M and Musa AG:
Monitoring cancer antigen 125 levels in induction chemotherapy for
epithelial ovarian carcinoma and predicting outcome of second-look
procedure. Gynecol Oncol. 57:178–182. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Urban N, McIntosh MW, Andersen M and
Karlan BY: Ovarian cancer screening. Hematol Oncol Clin North Am.
17:989–1005, ix. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jacobs I and Bast RC: The CA 125
tumour-associated antigen: A review of the literature. Hum Reprod.
4:1–12. 1989.PubMed/NCBI
|
|
9
|
Moore RG, Brown AK, Miller MC, Badgwell D,
Lu Z, Allard WJ, Granai CO, Bast RC and Lu K: Utility of a novel
serum tumor biomarker HE4 in patients with endometrioid
adenocarcinoma of the uterus. Gynecol Oncol. 110:196–201. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Levanon K, Crum C and Drapkin R: New
insights into the pathogenesis of serous ovarian cancer and its
clinical impact. J Clin Oncol. 26:5284–5293. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Holcomb K, Vucetic Z, Miller MC and Knapp
RC: Human epididymis protein 4 offers superior specificity in the
differentiation of benign and malignant adnexal masses in
premenopausal women. Am J Obstet Gynecol. 205:358.e1–6. 2011.
View Article : Google Scholar
|
|
12
|
Hamed EO, Ahmed H, Sedeek OB, Mohammed AM,
Abd-Alla AA and Abdel Ghaffar HM: Significance of HE4 estimation in
comparison with CA125 in diagnosis of ovarian cancer and assessment
of treatment response. Diagn Pathol. 8:112013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kadija S, Stefanovic A, Jeremic K,
Radojevic MM, Nikolic L, Markovic I and Atanackovic J: The utility
of human epididymal protein 4, cancer antigen 125, and risk for
malignancy algorithm in ovarian cancer and endometriosis. Int J
Gynecol Cancer. 22:238–244. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sandri MT, Bottari F, Franchi D, Boveri S,
Candiani M, Ronzoni S, Peiretti M, Radice D, Passerini R and Sideri
M: Comparison of HE4, CA125 and ROMA algorithm in women with a
pelvic mass: Correlation with pathological outcome. Gynecol Oncol.
128:233–238. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Moore RG, Jabre-Raughley M, Brown AK,
Robison KM, Miller MC, Allard WJ, Kurman RJ, Bast RC and Skates SJ:
Comparison of a novel multiple marker assay vs the Risk of
Malignancy Index for the prediction of epithelial ovarian cancer in
patients with a pelvic mass. Am J Obstet Gynecol. 203:228.e1–6.
2010. View Article : Google Scholar
|
|
16
|
Park Y, Kim Y, Lee EY, Lee JH and Kim HS:
Reference ranges for HE4 and CA125 in a large Asian population by
automated assays and diagnostic performances for ovarian cancer.
Int J Cancer. 130:1136–1144. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Moore RG, McMeekin DS, Brown AK,
DiSilvestro P, Miller MC, Allard WJ, Gajewski W, Kurman R, Bast RC
and Skates SJ: A novel multiple marker bioassay utilizing HE4 and
CA125 for the prediction of ovarian cancer in patients with a
pelvic mass. Gynecol Oncol. 112:40–46. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Toss A, De Matteis E, Rossi E, Casa LD,
Iannone A, Federico M and Cortesi L: Ovarian cancer: Can proteomics
give new insights for therapy and diagnosis? Int J Mol Sci.
14:8271–8290. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yancik R: Ovarian cancer. Age contrasts in
incidence, histology, disease stage at diagnosis, and mortality.
Cancer. 71(Suppl 2): 517–523. 1993.PubMed/NCBI
|
|
20
|
Molina R, Escudero JM, Augé JM, Filella X,
Foj L, Torné A, Lejarcegui J and Pahisa J: HE4 a novel tumour
marker for ovarian cancer: Comparison with CA 125 and ROMA
algorithm in patients with gynaecological diseases. Tumour Biol.
32:1087–1095. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lowe KA, Shah C, Wallace E, Anderson G,
Paley P, McIntosh M, Andersen MR, Scholler N, Bergan L, Thorpe J,
et al: Effects of personal characteristics on serum CA125,
mesothelin, and HE4 levels in healthy postmenopausal women at
high-risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev.
17:2480–2487. 2008. View Article : Google Scholar : PubMed/NCBI
|
